Huang Chunmei, Kim Youngki, Caramori Maria Luiza A, Fish Alfred J, Rich Stephen S, Miller Michael E, Russell Gregory B, Mauer Michael
Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Diabetes. 2002 Dec;51(12):3577-81. doi: 10.2337/diabetes.51.12.3577.
Transforming growth factor-beta (TGF-beta) may be critical in the development of diabetic nephropathy (DN), and genetic predisposition is an important determinant of DN risk. We evaluated mRNA expression levels of TGF-beta system components in cultured skin fibroblasts (SFs) from type 1 diabetic patients with fast versus slow development of DN. A total of 125 long-standing type 1 diabetic patients were ranked by renal mesangial expansion score (MES) based on renal biopsy findings and diabetes duration. Patients in the highest quintile of MES who were also microalbuminuric or proteinuric (n = 16) were classified as "fast-track" for DN, while those in the lowest quintile who were also normoalbuminuric (n = 23) were classsified as "slow-track" for DN. Twenty-five normal subjects served as control subjects. SFs were cultured in medium with 25 mmol/l glucose for 36 h. SF mRNA expression levels for TGF-beta1, TGF-beta type II receptor (TGF-beta RII), thrombospondin-1, and latent TGF-beta binding protein-1 (LTBP-1) were measured by real-time RT-PCR. LTBP-1 mRNA expression was reduced in slow-track (0.99 +/- 0.38) versus fast-track patients (1.65 +/- 0.52, P = 0.001) and control subjects (1.41 +/- 0.7, P = 0.025). mRNA levels for TGF-beta1, TGF-beta RII, and thrombospondin-1 were similar in the three groups. Reduced LTBP-1 mRNA expression in SFs from slow-track patients may reflect genetically determined DN protection and suggests that LTBP-1 may be involved in the pathogenesis of DN through the regulation of TGF-beta activity.
转化生长因子-β(TGF-β)可能在糖尿病肾病(DN)的发展中起关键作用,而遗传易感性是DN风险的重要决定因素。我们评估了1型糖尿病患者中,DN发展快与慢的患者培养的皮肤成纤维细胞(SFs)中TGF-β系统成分的mRNA表达水平。根据肾活检结果和糖尿病病程,对总共125例长期1型糖尿病患者进行肾系膜扩张评分(MES)排名。MES处于最高五分位数且伴有微量白蛋白尿或蛋白尿的患者(n = 16)被归类为DN的“快速进展型”,而MES处于最低五分位数且尿白蛋白正常的患者(n = 23)被归类为DN的“缓慢进展型”。25名正常受试者作为对照。将SFs在含25 mmol/l葡萄糖的培养基中培养36小时。通过实时RT-PCR测量TGF-β1、TGF-β II型受体(TGF-β RII)、血小板反应蛋白-1和潜伏性TGF-β结合蛋白-1(LTBP-1)的SF mRNA表达水平。与快速进展型患者(1.65 +/- 0.52,P = 0.001)和对照受试者(1.41 +/- 0.7,P = 0.025)相比,缓慢进展型患者(0.99 +/- 0.38)的LTBP-1 mRNA表达降低。三组中TGF-β1、TGF-β RII和血小板反应蛋白-1的mRNA水平相似。缓慢进展型患者SFs中LTBP-1 mRNA表达降低可能反映了基因决定的DN保护作用,并表明LTBP-1可能通过调节TGF-β活性参与DN的发病机制。